These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20635973)

  • 21. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts.
    Mohty M; Olive D; Gaugler B
    Leukemia; 2002 Nov; 16(11):2197-204. PubMed ID: 12399962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
    Ebstein F; Sapede C; Royer PJ; Marcq M; Ligeza-Poisson C; Barbieux I; Cellerin L; Dabouis G; Grégoire M
    Am J Respir Crit Care Med; 2004 Jun; 169(12):1322-30. PubMed ID: 15070823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
    Avigan D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells: tools and targets for antitumor vaccination.
    den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
    Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
    Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
    J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
    Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.
    Koido S; Homma S; Hara E; Namiki Y; Ohkusa T; Gong J; Tajiri H
    J Biomed Biotechnol; 2010; 2010():752381. PubMed ID: 20379390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.
    Koido S
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cells.
    Tomiyama M; Takahara M; Egawa K; Nieda M
    Anticancer Res; 2004; 24(5C):3327-33. PubMed ID: 15515428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes.
    Neidhardt-Berard EM; Berard F; Banchereau J; Palucka AK
    Breast Cancer Res; 2004; 6(4):R322-8. PubMed ID: 15217499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic-tumor fusion cells in cancer immunotherapy.
    Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S
    Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy.
    Wu Y; Wang L; Zhang Y
    Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
    López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
    Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.
    Vo MC; Nguyen-Pham TN; Lee HJ; Jaya Lakshmi T; Yang S; Jung SH; Kim HJ; Lee JJ
    Oncotarget; 2017 Apr; 8(16):27252-27262. PubMed ID: 28460478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic-cell vaccination for prostate cancer.
    Thomas-Kaskel AK; Veelken H
    Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.